D
Daniel O'malley
Researcher at Bristol-Myers Squibb
Publications - 22
Citations - 185
Daniel O'malley is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Cancer & Tricyclic. The author has an hindex of 7, co-authored 22 publications receiving 145 citations.
Papers
More filters
Patent
Carbazole compounds useful as bromodomain inhibitors
Michael A. Poss,David R. Tortolani,Dharmpal S. Dodd,Mussari Christopher P,John S. Tokarski,Ashvinikumar V. Gavai,Yufen Zhao,George V. Delucca,Daniel O'malley,Derek J. Norris,Patrice Gill,Claude A. Quesnelle,Wen-Ching Han +12 more
TL;DR: The present invention is directed to carbazole compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
Patent
Tricyclic compounds as anticancer agents
Derek J. Norris,George V. Delucca,Ashvinikumar V. Gavai,Claude A. Quesnelle,Patrice Gill,Daniel O'malley,Wayne Vaccaro,Francis Y. Lee,Mikkel V. Debenedetto,Andrew P. Degnan,Haiquan Fang,Matthew D. Hill,Hong Huang,William D. Schmitz,JR John E. Starrett,Wen-Ching Han,John S. Tokarski,Mandal Sunil Kumar +17 more
TL;DR: The present invention is directed to tricyclic compounds (I), pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders as discussed by the authors.
Journal Article
Molecular Cytogenetic Mapping of the Human Melanoma Antigen (MAGE) Gene Family to Chromosome Region Xq27-qter: Implications for MAGE Immunotherapy
TL;DR: It is believed that patients enrolled in MAGE-specific immunotherapy trials should be carefully monitored for the presence of MAGE antigen-loss variants.
Journal ArticleDOI
Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design.
Ashvinikumar V. Gavai,Derek J. Norris,George V. Delucca,David R. Tortolani,John S. Tokarski,Dharmpal S. Dodd,Daniel O'malley,Yufen Zhao,Claude A. Quesnelle,Patrice Gill,Wayne Vaccaro,Tram N. Huynh,Vijay T. Ahuja,Wen-Ching Han,Mussari Christopher P,Lalgudi S. Harikrishnan,Muthoni G. Kamau,Michael A. Poss,Steven Sheriff,Chunhong Yan,Frank Marsilio,Krista Menard,Mei-Li Wen,Richard Rampulla,Dauh-Rurng Wu,Jianqing Li,Huiping Zhang,Peng Li,Dawn Sun,Henry Yip,Sarah C. Traeger,Yingru Zhang,Arvind Mathur,Haiying Zhang,Christine Huang,Zheng Yang,Asoka Ranasinghe,Gerry Everlof,Nirmala Raghavan,Ching Kim Tye,Susan Wee,John T. Hunt,Gregory D. Vite,Richard A. Westhouse,Francis Y. Lee +44 more
TL;DR: In this article, a combination of structure-activity relationship and protein structure-guided drug design led to the discovery of a differently oriented carbazole 9 with favorable binding to the tryptophan, proline, and phenylalanine (WPF) shelf conserved in the BET family.
Journal ArticleDOI
Discovery of Pyridazinone and Pyrazolo[1,5-a]pyridine Inhibitors of C-Terminal Src Kinase
Daniel O'malley,Vijay T. Ahuja,Brian E. Fink,Carolyn Cao,Cindy Wang,Jesse Swanson,Susan Wee,Ashvinikumar V. Gavai,John S. Tokarski,David A Critton,Anthony A. Paiva,Benjamin M. Johnson,Nicolas Szapiel,Dianlin Xie +13 more
TL;DR: C-terminal Src kinase functions as a negative regulator of T cell activation through inhibitory phosphorylation of LCK, so inhibitors of CSK are of interest as potential immuno-oncology agents.